Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression

References

• Bombeiro AL, Pereira BTN, de Oliveira ALR. 2018. Granulocyte-macrophage colony-stimulating factor improves mouse peripheral nerve regeneration following sciatic nerve crush. Eur J Neurosci. 48(5):2152–2164.
   PubMed Web of Science ®Google Scholar
• Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F. 2009. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 116(3):214–217.
   PubMed Web of Science ®Google Scholar
• Brunoni AR, Machado-Vieira R, Zarate CA, Valiengo L, Vieira EL, Bensenor IM, Lotufo PA, Gattaz WF, Teixeira AL. 2014. Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology. 231(7):1315–1323.
   PubMed Web of Science ®Google Scholar
• Carboni L, McCarthy DJ, Delafont B, Filosi M, Ivanchenko E, Ratti E, Learned SM, Alexander R, Domenici E. 2019. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry. 9(1):182.
   PubMedGoogle Scholar
• Chen CY, Yeh YW, Kuo SC, Liang CS, Ho PS, Huang CC, Yen CH, Shyu JF, Lu RB, Huang SY. 2018. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Psychoneuroendocrinology. 87:108–118.
   PubMed Web of Science ®Google Scholar
• Cohen, J., 1988. Statistical power analysis for the behavioral sciences. Hillsdale (NJ): Lawrence Erlbaum Associates.
   Google Scholar
• Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 9(1):46–56.
   PubMed Web of Science ®Google Scholar
• Dooley LN, Kuhlman KR, Robles TF, Eisenberger NI, Craske MG, Bower JE. 2018. The role of inflammation in core features of depression: insights from paradigms using exogenously-induced inflammation. Neurosci Biobehav Rev. 94:219–237.
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Huang H, Thase ME. 2001. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 62(11):869–877.
   PubMed Web of Science ®Google Scholar
• Ferrier IN. 1999. Treatment of major depression: is improvement enough? J Clin Psychiatry. 60(Suppl 6):10–14.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JB. 2002. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. SCID-I/P New York, NY, USA.
   Google Scholar
• Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M. 2013. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord. 145(3):300–307.
   PubMed Web of Science ®Google Scholar
• Gadad BS, Jha MK, Grannemann BD, Mayes TL, Trivedi MH. 2017. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: findings from the CO-MED trial. J Psychiatr Res. 94:1–6.
   PubMed Web of Science ®Google Scholar
• Glassman CR, Su L, Majri-Morrison SS, Winkelmann H, Mo F, Li P, Perez-Cruz M, Ho PP, Koliesnik I, Nagy N, et al. 2021. Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. Elife. 10:e65777.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 21(12):1696–1709.
   PubMed Web of Science ®Google Scholar
• Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. 2013. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013(12):CD008851.
   Google Scholar
• Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. 2011. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 25(2):335–339.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:56–62.
   Web of Science ®Google Scholar
• Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T. 2005. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol. 20(3):151–156.
   PubMed Web of Science ®Google Scholar
• Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, Sunada N, Onohara A, Hatashita Y, Serretti A, et al. 2017. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res. 89:97–104.
   PubMed Web of Science ®Google Scholar
• Kato M. UMIN-CTR Clinical Trial. 2011. Investigation of biological and clinical predictor of antidepressant response for personalized medicine in depression; a randomized controlled trial. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007612.
   Google Scholar
• Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, et al. 2017. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 7(3):e1065.
   PubMedGoogle Scholar
• Liu Y, Ho RC, Mak A. 2012. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 139(3):230–239.
   PubMed Web of Science ®Google Scholar
• Marini S, Vellante F, Matarazzo I, De Berardis D, Serroni N, Gianfelice D, Olivieri L, Di Renzo F, Di Marco A, Fornaro M, et al. 2016. Inflammatory markers and suicidal attempts in depressed patients: a review. Int J Immunopathol Pharmacol. 29(4):583–594.
   PubMed Web of Science ®Google Scholar
• O’Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. 2013. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 16(10):2259–2272.
   PubMed Web of Science ®Google Scholar
• Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. 2018. The blood-brain barrier in psychosis. Lancet Psychiatry. 5(1):79–92.
   PubMed Web of Science ®Google Scholar
• Pollak Y, Yirmiya R. 2002. Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol. 5(4):389–399.
   PubMed Web of Science ®Google Scholar
• Powell ND, Sloan EK, Bailey MT, Arevalo JM, Miller GE, Chen E, Kobor MS, Reader BF, Sheridan JF, Cole SW. 2013. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via β-adrenergic induction of myelopoiesis. Proc Natl Acad Sci USA. 110(41):16574–16579.
   PubMed Web of Science ®Google Scholar
• Quinn ME, Stanton CH, Slavich GM, Joormann J. 2020. Executive control, cytokine reactivity to social stress, and depressive symptoms: testing the social signal transduction theory of depression. Stress. 23(1):60–68.
   PubMed Web of Science ®Google Scholar
• Reynolds JL, Ignatowski TA, Spengler RN. 2005. Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor. J Neurosci Res. 79(6):779–787.
   PubMed Web of Science ®Google Scholar
• Ricken R, Busche M, Schlattmann P, Himmerich H, Bopp S, Bschor T, Richter C, Stamm TJ, Heinz A, Hellweg R, et al. 2018. Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression. J Psychiatr Res. 96:203–208.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, Inada K, Kikuchi T, Katsuki A, Kishida I. et al. 2020. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 266:626–632.
   PubMed Web of Science ®Google Scholar
• Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, et al. 2008. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab. 28(1):29–43.
   PubMed Web of Science ®Google Scholar
• Schefold JC, Zeden JP, Pschowski R, Hammoud B, Fotopoulou C, Hasper D, Fusch G, Von Haehling S, Volk HD, Meisel C, et al. 2010. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand J Infect Dis. 42(3):164–171.
   PubMed Web of Science ®Google Scholar
• Schiepers OJ, Wichers MC, Maes M. 2005. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 29(2):201–217.
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Schroder T, Kirkby KC, Sander C, Suslow T, Holdt LM, Teupser D, Hegerl U, Himmerich H. 2016. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 239:85–91.
   PubMed Web of Science ®Google Scholar
• Tang Z, Ye G, Chen X, Pan M, Fu J, Fu T, Liu Q, Gao Z, Baldwin DS, Hou R. 2018. Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. J Affect Disord. 225:593–598.
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y. 2005. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 66(08):974–981.
   PubMedGoogle Scholar
• Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. 2010. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 25(4):189–198.
   PubMed Web of Science ®Google Scholar
• Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. 2003. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 305(1):197–204.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wei H, Zhu Y, Zhu Y, Zhang N, Qin J, Zhu X, Yu M, Li Y. 2019. Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression. J Affect Disord. 250:307–312.
   PubMed Web of Science ®Google Scholar
• World Health Organization, 2008. The Global Burden of Disease 2004 Update. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
   Google Scholar
• Zhang J, Yue Y, Thapa A, Fang J, Zhao S, Shi W, Yang Z, Li Y, Yuan Y. 2019. Baseline serum C-reactive protein levels may predict antidepressant treatment responses in patients with major depressive disorder. J Affect Disord. 250:432–438.
   PubMed Web of Science ®Google Scholar
• Zunszain PA, Hepgul N, Pariante CM. 2013. Inflammation and depression. Curr Top Behav Neurosci. 14:135–151.
   PubMedGoogle Scholar